Vibrant Gastro

Company Overview

Snapshot

Founded in September 2007, Vibrant Gastro operates with 11–50 employees. The company has raised $7.5 million across 3 funding rounds from 4 investors, with Unorthodox Ventures participating as a lead investor. In May 2022, Vibrant Gastro announced positive efficacy and safety results for its novel drug-free treatment in a pivotal Phase 3 study for adults with chronic idiopathic constipation.

Business overview

Vibrant Gastro develops the Synchronized Activation Method, a drug-free technology system that uses gentle vibrations to mechanically stimulate the colon. This preprogrammed timing aims to improve natural colonic motility by leveraging the colon’s biological clock. The technology is designed for future data-driven personalized treatments and additional indications leveraging the gut-brain connection via the enteric nervous system pathway. The company's initial focus is on treating adults with chronic idiopathic constipation who have not found relief from laxative therapies, operating within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Digital Therapeutics.

Strategic signal

In May 2022, Vibrant Gastro announced positive efficacy and safety results from a pivotal Phase 3 study for its novel drug-free treatment for chronic idiopathic constipation. This milestone is a significant validation of the company's technology, signaling to investors and the medical community a potential breakthrough in non-pharmacological approaches to a widespread gastrointestinal condition, and indicating a strong trajectory towards market adoption.

Company Intelligence Q&A

What is Vibrant Gastro's core technology?

Vibrant Gastro develops the Synchronized Activation Method, a drug-free technology system that uses gentle vibrations to mechanically stimulate the colon, aiming to improve natural colonic motility.

When did Vibrant Gastro complete clinical studies for its vibrating capsule?

In October 2017, Vibrant Gastro successfully completed two clinical studies showcasing the efficacy of its vibrating capsule for treating chronic constipation.

What were the results of Vibrant Gastro's Phase 3 study?

In May 2022, Vibrant Gastro's novel drug-free treatment demonstrated positive efficacy and safety results in a pivotal Phase 3 study for adults with chronic idiopathic constipation.

Which investors participated in Vibrant Gastro's March 2021 funding round?

In March 2021, Vibrant Gastro raised funding led by.

What is the primary indication for Vibrant Gastro's treatment?

Vibrant Gastro's first indication is for treating adults with chronic idiopathic constipation who have not experienced relief from laxative therapies.